Evidence map›Paper›PMID 40977752›Full record

ReviewDermatology research and practice2025

JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases.

Saeed Bahramian, Patrick Fazeli, Arezou Rafati, Sardar Demokri, Huria Memari, Amirali Soheili, Farzad Esmaeili, Mohammad Pourmehdi Ardebili, Haniye Erfani, Seyed Mohammad Vahabi

Abstract readReview
In one paragraph

Review in Dermatology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Saeed BahramianSchool of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Patrick FazeliDivision of Biology & Medicine, Brown University, Providence, Rhode Island, USA.ORCID https://orcid.org/0000-0003-4394-8929
Arezou RafatiSchool of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Sardar DemokriSchool of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Huria MemariSchool of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.ORCID https://orcid.org/0000-0003-0104-5350
Amirali SoheiliRajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
Farzad EsmaeiliSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-2265-9995
Mohammad Pourmehdi ArdebiliSchool of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
Haniye ErfaniSchool of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Seyed Mohammad VahabiDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-4736-6803

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

JAK inhibitorsJanus kinaseUBA1 mutationVEXAS syndrome

Identifiers

PMID40977752
PMCPMC12449113

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.